Public Health & Policy Issues: Illegal Drugs Sheila M. Bird MRC Biostatistics Unit, Cambridge Collaborations: Sharon Hutchinson & David Goldberg, HPS Brian.

Slides:



Advertisements
Similar presentations
Performance Monitoring in the Public Services. Challenges, opportunities, pitfalls (failed) Challenge: Performance Monitoring in the Public Services (missed)
Advertisements

Predictors of Change in HIV Risk Factors for Adolescents Admitted to Substance Abuse Treatment Passetti, L. L., Garner, B. R., Funk, R., Godley, S. H.,
Hepatitis C prevention among people who inject drugs: reducing transmission in PWID by scaling up HCV treatment, OST and needle exchange services Matt.
Mortality and causes of death among women living with HIV in the UK in the era of highly-active antiretroviral therapy Sara Croxford, A Kitching, M Kall,
Delay from Testing HIV Positive until First HIV Care for Drug Users: Adverse Consequences and Possible Solutions Barbara J Turner MD, MSEd* John Fleishman.
HIV in the United Kingdom: 2013 HIV and AIDS Reporting Section Centre for Infectious Disease Surveillance and Control (CIDSC) Public Health England London,
The hidden HIV epidemic: what do mathematical models tell us? The case of France Virginie Supervie, Jacques Ndawinz & Dominique Costagliola U943 Inserm.
Hepatitis C Action Plan Prevention Working Group Findings and recommendations Norah Palmateer Health Protection Scotland Greater Glasgow & Clyde MCN June.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2013.
HIV Risk Behaviors and Alcohol Intoxication among Injection Drug Users in Puerto Rico Tomás D. Matos, MS Center for Addiction Studies Universidad Central.
Drug-Related Deaths (DRDs) soon after release: I Effectiveness on Trial: II Naloxone (heroin antidote) on release to reduce overdose deaths
Criminal Designs Sheila M. Bird MRC Biostatistics Unit, CAMBRIDGE CB2 2SR.
Killing the Pain: Prescription Drug Abuse and Other Risky Behaviors in Rural Appalachia Jennifer R. Havens, PhD, MPH Department of Behavioral Science Center.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence September–October 2008.
Addiction Treatment Outcomes Prof Michael Gossop National Addiction Centre Maudsley Hospital/Institute of Psychiatry.
Tuberculosis in the UK 2013 report
HIV Infection Among Those with an Injection Drug Use*- Associated Risk, Florida, 2012 Florida Department of Health HIV/AIDS and Hepatitis Section Division.
A Webinar Hosted by The National Harm Reduction Coalition The National Black Leadership Commission on AIDS The Coalition for Positive Health Empowerment.
The UK Drugs Situation: Data, information and uses Charlotte Davies, UK Focal Point Project Manager 1.
Guidance on Provider-initiated Voluntary Medical Examination, Testing and Counselling for Infectious Diseases in Injecting Drug Users Hans Blystad 1 and.
Modelled impact of antiviral therapy on the future burden of HCV disease in Scotland Testing/Treatment/Care Working Group, 11 th Sept 2007.
HIV research in the era of ART: changing priorities in Tanzania Basia Zaba SOAS 3 rd March 2011.
Meeting the health needs of older drug users Dr Muriel Simmonte NHS Lothian Primary Care Facilitator Team/East Lothian Locality Drug Clinic.
Nino Maddalena Criminal Justice Manager National Treatment Agency.
NICE Decision Making Dr Katherine Payne North West Genetics Knowledge Park The University of Manchester
Hepatitis C, Drug Use and Stigma Liz Allen. What it is Hepatitis C? Hepatitis C is a blood-borne virus Can cause serious damage to the liver First indentified.
Effects of an HIV/AIDS peer prevention intervention on sexual and injecting risk behaviors among injecting drug users (IDUs) and their risk partners in.
Rediscovering Recovery: A Revolution in UK Drug Treatment Policy Neil McKeganey Professor of Drug Misuse Research University of Glasgow.
MRCPsych seminar series Epidemiology of addictive disorders: a brief review Dr Stuart McLaren March 2010.
All Change! Infections, injecting drug use and harm reduction. Vivian Hope IDU Team, HIV & STI Department, Health Protection Services – Colindale Dr Vivian.
Tackling hepatitis C - what PHE modelling shows us Helen Harris BSc PhD FFPH LJWG meeting; November 2014.
Thailand is located at the Golden Triangle: Population: 65 millions Current Status of Drug Use and HIV in Thailand Apinun Aramrattana, MD, PhD Faculty.
If I ruled the world… Presentation to Prisons and Beyond NOMS Prison Drug Strategy Unit, in association with the Federation of Drug & Alcohol Professionals.
Drug Use and Hepatitis C Are we mindful of the gaps? Dave Liddell, SDF.
HIV and STI Department, Health Protection Agency - Colindale HIV and AIDS Reporting System HIV in the United Kingdom: 2012 Overview.
Drug and Alcohol Misuse Dr Mick McKernan. Harm Reduction Philosophy to lessen the dangers drug abuse cause to Individual/society We will never stop drug.
HIV Infection Among Those with an Injection Drug Use*-Associated Risk, Florida, 2014 Florida Department of Health HIV/AIDS Section Division of Disease.
HCV in injecting drug users: developing indicators of prevalence and responses VHPB WHO Consultation Meeting Geneva, 13 May 2002 Lucas Wiessing European.
1 Kennedy Roberts Senior Medical Officer and Clinical Lead North Cluster Glasgow Addiction Services Community Addiction Teams What are the challenges for.
EMCDDA Work Programme Key Issue 1: Key Indicators 30th Meeting of Scientific Committee J Vicente (together with D Olszewski, D Klempova, L Montanari,
A prevalence study of alcohol amongst offenders in the probation and prison services in North East England Dr. Dorothy Newbury-Birch Senior Research Associate.
Role of harm reduction in HCV prevention in France: from research to scale up Bruno Spire & Patrizia Carrieri.
Department of SOCIAL MEDICINE University of BRISTOL The primary prevention of hepatitis C among injectors: model projections of the impact of opiate substitution.
Pennsylvania: The State of HCV 2015
Kow-Tong Chen, M.D., Ph.D., Hsiao-Ling Chang, Ph.D., Chu-Tzu Chen, M.P.H., and Ying-An Chen, M.P.H. Volume 23, Number 3, 2009 AIDS PATIENT CARE and STDs.
NCI ANNUAL REPORT 2013 © National Confidential Inquiry into Suicide and Homicide by People with Mental Illness. All rights reserved. Not to be reproduced.
HIV Infection among Those with an Injection Drug Use*-Associated Risk, Florida, 2011 HIV/AIDS & Hepatitis Program *Injection Drug Use (IDU) data in this.
Understanding temporal trends in HIV prevalence, incidence and ARV Dr Valerie Delpech Head of HIV surveillance Public Health England.
Decline in incidence of HIV and Hepatitis C virus infection among injecting drug users in Amsterdam; evidence for harm reduction? 1. Julius Center, University.
Hepatitis C: The Silent Epidemic Wednesday, October 21, 2015 John W. Ward, M.D. Division of Viral Hepatitis Centers for Disease Control and Prevention.
Jennifer R. Havens, PhD, MPH Associate Professor
Formal experiments: randomisation + study size. Concept of randomisation Biology, 1926: Sir Ronald Fisher Medicine, 1947: Sir Austin Bradford Hill Randomised.
Factors associated with concurrent Heroin use among patients on Methadone maintenance treatment in Vietnam from 2008 to 2013 Hoang Nam Thai MD, MPH – CDC/DGHT.
…Implications for Wales Josie Smith Programme Lead for Substance Misuse, Public Health Wales TOWARDS A HEALTH BASED APPROACH.
Alcohol and other drugs Amber Jefferson Drug Surveys and Services Unit.
Universal Opt-Out Screening for HIV in Health Care Settings, Cost Effectiveness in Action Douglas K. Owens, MD, MS VA Palo Alto Health Care System and.
NPS and Importance of Information Sharing Dr Richard Stevenson A&E Department, Glasgow Royal Infirmary Dr Hazel Torrance Forensic Medicine and Science.
South West Hepatitis C Needs Assessment Dr Maya Gobin Health Protection Services (South West)
Services and C Leon Wylie Lead Officer Hepatitis Scotland.
PREVENTION OF DRUG ABUSE AMONG VULNERABLE GROUPS Dr Marcus Roberts Director of Policy and Membership DRUGSCOPE.
Prison Health: The Scottish Experience 3 rd Feb 2015 Wrexham Dr Lesley Graham Public Health Lead for Alcohol, Drugs and Health & Justice Information Services.
What is the contribution of alcohol to liver disease in the hepatitis C infected population. The epidemiological evidence Hamish Innes Research Fellow.
Non-Medical Staff Knowledge, Beliefs and Practices about HIV and Hepatitis for Injection Drug Users Rowe, KA 1, Tesoriero, JM 1, Heavner, KK 1, Rothman,
 Reliant on robust monitoring systems  Emphasis changed over time  Limited by data collection systems available  Data collection adapts to allow wider.
GOVERNMENT OFFICE FOR THE SOUTH WEST South West Public Health Observatory GOVERNMENT OFFICE FOR THE SOUTH WEST South West Public Health Observatory Drug.
HIV treatment cascade analysis for people who inject drugs in Ukraine: identifying the correlates of HIV care outcomes Kostyantyn Dumchev1, Olga Varetska2,
National Confidential Inquiry into Suicide and Homicide by People with Mental Illness Annual Report 2017.
Hepatitis B and C management pathways in prison:
National estimation of the prevalence of problem drug use: revisiting and extending multiplier methods in a multi-parameter evidence synthesis framework.
Blood borne viral hepatitis action in Wales
Presentation transcript:

Public Health & Policy Issues: Illegal Drugs Sheila M. Bird MRC Biostatistics Unit, Cambridge Collaborations: Sharon Hutchinson & David Goldberg, HPS Brian Tom, Bo Fu & Elizabeth Merrall, BSU Ruth King & Gordon St Andrews & Glasgow

Keep Injecting iLLEgal Drugs Murder Suicide Overdose Late sequelae of Hepatitis C Late sequelae of HIV Late sequelae of alcohol as co-factor Public costs. IDU  socially transmissible disease IDU  courts, prison, health & drug services

Keep Injecting iLLEgal Drugs Projecting Scottish IDUs’ late HCV sequelae required Past & recent injector incidence Past & recent off-injecting rates Past & recent drug-related death rates Other causes’ death-rate for ex-IDUs BBV transmission model: HCV infectiousness & prevalence, injecting frequency/partners BBV progression model: age at HCV infection, sex, alcohol co-factor, antiviral treatment BBV late sequelae: database linkage from HCV diagnoses (minimally) Costs overlay; policy changes; “if scenarios”.

Year Living IDUs (thousands) Modelled prevalent IDUs in Scotland ? doubled from and again from Current & former IDUs Current IDUs

Scotland’s HCV Action Plan (Hutchinson, Bird & Goldberg. Hepatology 2005; 42: ) Despite harm reduction policies, high HCV incidence ~ per 100 susceptible IDU-years. Past IDU epidemic’s current consequences: epidemic wave of DRDs in older current-IDUs ex-IDUs aged years: HCV test & treat (to halt HCV progression) Clean needles don’t prevent DRDs: off-injecting does + reducing IDU initiations. Only HCV-contaminated works infect: ? count HCV-contaminated injections since last –ve test.

National Institute for Health & Clinical Excellence: threshold of £20-30K per QALY NICE on Needle Exchange (NE): without comment, high baseline cost-per-QALY for IDUs of £38K to £45K. (UK-unaffordable) Possible NICE decision = HCV test every 6 months. This was not modelled... NICE Appraisal is Evidence + Judgment. Decision follows from 30% to 50% HCV prevalence among IDUs, transmission risk of 2% or 3% per contaminated injection  25% HCV risk after 10 contaminated injections. “What if” added IDU-years/DRDs facilitated by NE: was not modelled.

Missed UK target 20% reduction in Drug-Related Deaths by 2005 Policy implications?

Drugs-related deaths & Capture-Recapture (CR) in Scotland: ; ; Era Drugs-related deaths Classically-analysed CR of current injectors ~ 25,000 (reference year 2000/01) ~ 20,000 (reference year 2003/04) Oops... !!!

Scotland’s drug-related deaths by: age-group, gender, region EraScotland (male, female) Greater Glasgow (29%) Elsewhere in Scotland 15 – 34 years of age (83% male) public health success? (558, 114) (482, 90) Since (402, 64)

Scotland’s drug-related deaths by: age-group, gender, region EraScotland (male, female) Greater Glasgow (35%) Elsewhere in Scotland 35+ years of age (76% male) Ageing epidemic increase! (269, 65) (322,115) Since (325, 85)

Scotland’s drugs-related deaths & Bayesian CR estimates for current injectors (minor & major modes, King et al., SMMR in press) 3-year EraDrugs- Related Deaths Bayesian Capture-Recapture estimated for current IDUs: annual DRDs per 100 IDUs 2000 – (re 2000/01): (re 2003/04): 1.2 (HPDI: to )

Bayesian Capture-Recapture Not all DRDs occur in IDUs... Prior beliefs: % DRDs who are injectors? 80% for DRDs aged years (75% to 85%) 20% for DRDs aged 45+ years (15% to 35%).

Bayesian Capture-Recapture, ,20 estimate iDRD rate per 100 IDUs Gender & Age-group Greater Glasgow Elsewhere in Scotland BCR IDUs Rate (HPDI) BCR IDUs Rate: (HPDI) M, 15-34yrs (0.9, 1.4) (0.8, 1.2) M, (0.9, 1.5) (1.0, 1.7) F, 15-34yrs (0.3, 0.6) (0.3, 0.5) F, (0.7, 1.4) (1.0, 1.7)

21 st Century Drugs and Statistical Science in UK Surveys, Design & Statistics Subcommittee of HOSAC 1.Landscape: Now surveys with/without biological samples; databases; cohorts; biological sample collections; tangle of technologies 2. Methodology Matters Database linkage & ‘virtual’ cohorts; Capture-recapture methods to estimate #injectors; Epidemics – initiations & removals; Evidence-synthesis, and biases; Formal experiments: randomization & cost-effectiveness; Genetics 3. Essential New Questions 4. New Prospects

Landscape: Now National databases ~ give event-dates (physical, mental health & CJ morbidity + mortality)  access to biological samples. Cohorts ~ conventionally comprise individuals who meet eligibility criteria (born in week W; diagnosed with condition X in region R) & give informed consent for clinical or other re-contact. Identifiers ~ NIL, classificatory, linkable (such as master-index: initial of 1 st name, soundex surname, sex, date of birth  S B630 f ), or personal number (PNC, NI, etc); DNA. Deductive disclosure about individuals: safe havens for linkage & analysis of linked, longitudinal data.

Gamut of surveys, databases, cohorts, biological sample collections. Representative surveillance? Health sites Self-report + biological sample? Schools New questions? Incidence & recovery (R o ) New tests? HCV-RNA for injectors Longitudinal linkage of “health”, drug referral, criminal databases? Coherent reports of IDU debut; powerful re trajectories. Birth & at-risk cohorts? Costly, losses, lack power ‘Virtual’ cohorts? Event-dates without context. Formal experiments in criminal justice? Efficacy, safety & cost-effectiveness.

Methodology Matters Capture-recapture methods to estimate # current injectors POLICY PRIORITY for local estimates, v. capture propensities: 22 models v. all 2-way interactions... Assumptions matter: new CR results for England.

New estimates for current injectors: England REGION Bayesian estimate (95% credible interval) Localised, classical estimate (95% CI) East England 11.1K ( 9.6K; 12.9K) 9.4K ( 6.3K; 13.1K) LONDON 45.8K (34.8K; 60.6K) 17.9K (16.2K; 24.0K) North West 35.4K (31.5K; 39.7K) 22.1K (18.8K; 25.2K) South West 19.3K (16.8K; 22.0K) 17.4K (15.9K; 19.5K) York+Humber 31.8K (28.4K; 35.8K) 21.0K (19.9K; 22.8K) ENGLAND 204K (189K; 223K) 137K (133K; 149K)

Epidemics: initiations into, & removals from injecting Back-calculation from overdose deaths to heroin/IDU incidence: needs duration of injecting Assumptions matter: surely, removal rate increased in 21 st C? Injector careers: snapshot samples.

Referral to Edinburgh’s liver clinic in late 20 th C: non-uniform KAPLAN, typically in last half/quarter of incubation period to cirrhosis (Fu et al., 2007) Clinic patients (if only 5% of community patients routinely referred, rest near to cirrhosis): over-estimate % fast progressors e.g. 55% v. 33% re community Covariate effect size in clinic patients (such as heavy drinking): under-estimated re true effect in community

Judges prescribe sentence on lesser evidence than doctors prescribe medicines Is public aware?

Drug Treatment &Testing Orders (DTTOs) England & Wales: 210 clients Scotland: 96 clients Targets for DTTO clients in E&W: 6,000+ per annum DTTO clients: 21,000+ by end 2003

RSS Court DTTO-eligible offenders: do DTTOs work ? Off 1 DTTO Off 2 DTTO Off 3 alternative = Off 4 DTTO Off 5 alternative = Off 6 alternative = Count offenders’ deaths, re-incarcerations etc...

UK courts’ DTTO-eligible offenders: ? guess Off 7 DTTO [ ? ] Off 8 DTTO [ ? ] Off 9 DTTO [ ? ] Off10 DTTO [ ? ] Off11 DTTO [ ? ] Off12 DTTO [ ? ] Off13 DTTO [ ? ] Off14 DTTO [ ? ] (before/after) Interviews versus... [ ? ]

Evaluations-charade Failure to randomise Failure to find out about major harms Failure even to elicit alternative sentence  funded guesswork on relative cost-effectiveness Volunteer-bias in follow-up interviews Inadequate study size re major outcomes...

The ‘business’ of judging & Judicial counting...

Custodial sentence lengths Male, Adults, Magistrates’ court, single offences, 2004 E&W

Awash with data... urines... Compulsory Drugs Testing in the British Army

10% reduction in opiate +ve rate, weekday pattern in cannabis positive rates. National Offender Management Service in 21st C. 1.Weekend v. Mon-Wed v. Thurs/Fri testing. 2.Different test rate by prison: annual election for or against 5% rMDT! 3.Lowered % positive for cannabis & opiates between eras. 4. Prescribed methadone ~ rarely.

T=tests, P=prescribed methadone, O=opiates, C=cannabis (95% CI for rate per 1,000) Prisons which elected for 5% rMDT 2000/01 to 2002/03 Tests P= 12 O (48, 51) C (77, 81) 2004/05 to 2006/07 Tests P=419 O (42, 44) C (66, 70) Prisons which elected against 5% rMDT 2000/01 to 2002/03 Tests P= 4 O (33, 36) C (64, 68) 2004/05 to 2006/07 Tests P=332 O (30, 32) C (48, 51)

O=opiates, C=cannabis (95% CI: rate per 1,000) 3-yearsMon+Tues+WedThurs+FridaySat+Sunday Prisons which elected for 5% rMDT 2000/01 to 2002/03 Tests O= (46, 50) C = (78, 83) Tests (51, 56) (76, 85) Tests (40, 48) (69, 78) 2004/05 to 2006/07 Tests O= (41, 45) C = (70, 73) Tests (42, 46) (64, 70) Tests (38, 44) (56, 63) Prisons which elected against 5% rMDT 2000/01 to 2002/03 Tests O= (32, 36) C= (67, 72) Tests (32, 37) (59, 65) Tests (33, 40) (56, 66) 2004/05 to 2006/07 Tests O= (29, 33) C= (51, 56) Tests (30, 35) (45, 52) Tests (26, 32) (40, 47)

Formal experiments: drugs courts “Hugs, not Drugs”

Harveian Oration: De Testimonio Evidence + Judgment Efficacy (typically in RCTs) v. Safety (rare events) + Effectiveness (promise into practice) Designs that are fit for purpose... (delayed judgments... ) Signal:noise ratio (usual outcome).

Guardian Society: 17 Nov “Some statisticians are so severe that they would stop social policy making in its tracks. For example, Bird would forbid the government to introduce any policy that had not been assessed through controlled trials... ”

Increased Efficiency at Detection masked trend in soldiers’ cocaine use British Army, Accentuated Monday testing 2.Differential testing by rank: privates! 3. Lowered threshold for cocaine

Privates in British Army: cocaine Year: % of all tests on Mondays MondayTuesdayWednesday Mon-Wed. Positives in 3*15,000 tests Tests to nearest 100; cocaine positive rate per 1, : 54% 24, , , : 44% 23, , , : 36% 19, , , Cocaine +ve Rate per 1, fold increase in 5 years; Wed. rate = half Mon. rate

Essential New Questions [1] Age at/year of starting to inject & at off-injecting. {up to 5 snapshots} # Periods “off-injecting for a least 1 year” since injecting debut. # New initiates to injecting, in your presence, in the past year. {3 present: count each 1/3 rd responsible} # Injectors, known to you, who gave up injecting in past 2 years v. # injectors who died in past 2 years. {pause for reflection}

Four PQs for every CJ initiative PQ1: Minister, why no randomised controls? PQ2: Minister, why have judges not even been asked to document offender’s alternative sentence that this CJ initiative supplants? {cf electronic tagging} PQ3: What statistical power does Ministerial pilot have re well-reasoned targets? {or, just kite flying...} PQ4: Minister, cost-effectiveness is driven by longer-term health & CJ harms, how are these ascertained? {  database linkage}

Bayesian Capture-Recapture 80,20 point-estimate iDRD rate per 100 IDUs applied to Gender & Age-group Greater Glasgow Elsewhere in Scotland Rate Rate (HPDI) Rate Rate (HPDI) M,15-34 yrs (0.9, 1.4) (0.8, 1.2) M, (0.9, 1.5) (1.0, 1.7) F, yrs (0.3, 0.6) (0.3, 0.5) F, (0.7, 1.4) (1.0, 1.7)